#Enzyme Immunoassay Market Size

[luckydige45]

According to latest report, the global enzyme immunoassay market size was USD 18.11 billion in 2023, calculated at USD 18.82 billion in 2024 and is expected to reach around USD 26.55 billion by 2033, expanding at a CAGR of 3.9% from 2024 to 2033.

[kristinahertzz]

Protein Detection Quantification Market

Protein Detection Quantification Market Size, Share, Trends: Thermo Fisher Scientific Inc. Leads

Shift Towards Multiplex Protein Detection and Quantification Technologies for Comprehensive Proteome Analysis

Market Overview:

The Protein Detection Quantification Market is projected to grow at a CAGR of 6.5% from 2024 to 2031, reaching a value of USD 3.8 billion by 2031. North America dominates the market, accounting for a significant share of the global market.

Key metrics driving this growth include increasing R&D activities in proteomics and the rising prevalence of chronic diseases. The protein detection quantification market is expanding rapidly, owing to advances in proteomic technology and a growing emphasis on personalised therapy. The integration of artificial intelligence and machine learning into protein analysis instruments improves accuracy and efficiency, thus pushing market growth. 

DOWNLOAD FREE SAMPLE

Market Trends:

The protein detection quantification market is witnessing a significant shift towards multiplex technologies that allow simultaneous detection and quantification of multiple proteins. This trend is driven by the growing demand for comprehensive proteome analysis in various research and clinical applications. Multiplex assays offer advantages such as reduced sample volume requirements, increased throughput, and cost-effectiveness.

In 2023, the multiplex protein detection segment accounted for a substantial market share, with a projected CAGR of 7.2% from 2024 to 2031. This growth is fueled by the increasing adoption of multiplex technologies in drug discovery and biomarker identification processes. Recent industry developments include the launch of advanced multiplex protein detection platforms. For instance, a leading life sciences company introduced a high-plex protein detection system in 2023, capable of analyzing up to 1,000 proteins simultaneously from a single sample, catering to the growing demand for large-scale proteomics studies.

Market Segmentation:

Immunological methods dominate the protein detection quantification market, accounting for a significant portion of the global market share. Immunological approaches have emerged as the leading technology in the protein detection quantification industry, due to their high specificity, sensitivity, and versatility in identifying and measuring a diverse spectrum of proteins across multiple sample types.

Immunological procedures, such as enzyme-linked immunosorbent tests (ELISA), Western blotting, and immunohistochemistry, offer various benefits, including ease of use, quick findings, and the capacity to detect low-abundance proteins. Over the last two years, immunological approaches have experienced a 15% increase in use in the pharmaceutical and biotechnology industries. Recent advances in immunological approaches have centered on increasing sensitivity and multiplexing abilities. A leading manufacturer has launched a novel multiplexed immunoassay technology that can quantify up to 100 proteins from a single sample with femtogram-level sensitivity.

Market Key Players:

Prominent players in the protein detection quantification market include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Merck KGaA, PerkinElmer, Inc., Abcam plc, Becton, Dickinson and Company, Cell Signaling Technology, Inc., Promega Corporation, Qiagen N.V., Agilent Technologies, Inc., Quanterix Corporation, and Olink Proteomics AB. These companies are leading the market with their innovative approaches, extensive product portfolios, and robust distribution networks, continuously setting industry standards and driving market growth.

Contact Us:

Name: Hari Krishna

Email us: hari.krishna@aurorawaveintellects.com

Website: https://aurorawaveintellects.com/

[marketsndata]

Japan In Vitro Diagnostics Market Analysis 2031

Japan In Vitro Diagnostics Market size was valued at USD 2.5 billion in FY2023 and is expected to reach USD 3.5 billion in FY2031 with a CAGR of 4.2% for the forecast period between FY2024 and FY2031.The Japan in vitro diagnostics (IVD) market has witnessed significant growth and innovation, solidifying its position as a crucial component in the healthcare sector. IVD refers to medical tests conducted on samples like blood, urine, and tissues outside the human body to diagnose diseases and conditions. This market has experienced steady expansion in Japan due to factors such as an aging population, rising healthcare awareness, and technological advances. The country’s aging demographic has contributed to an increased demand for accurate and efficient diagnostic tools, particularly for age-related diseases like cancer, diabetes, and cardiovascular conditions. This has propelled investments in research and development, creating cutting-edge IVD technologies that offer faster results and improved accuracy.

Japan’s commitment to technological advancement is evident in its adoption of automation, molecular diagnostics, and point-of-care testing. These advancements have streamlined diagnostic procedures, enabling quicker diagnoses and informed medical decisions. Additionally, collaborations between research institutions, healthcare providers, and industry players have fostered a conducive environment for innovation. Regulatory agencies like the Pharmaceuticals and Medical Devices Agency (PMDA) oversee the approval and quality control of IVD products, ensuring patient safety and product efficacy. Market players are focused on complying with these regulations while continuously refining their offerings. The Japan in vitro diagnostics market presents opportunities for domestic and international companies to contribute to the evolving healthcare landscape.

Advancement in Immunodiagnostics

In Japan, significant advancements in immunodiagnostics within the field of in vitro diagnostics have propelled healthcare efficacy. Cutting-edge technologies such as enzyme-linked immunosorbent assays (ELISAs), polymerase chain reaction (PCR) techniques, and flow cytometry have been integrated into diagnostic protocols, enabling rapid and accurate identification of various diseases. Collaborations between academia, industry, and research institutions have fostered the development of novel biomarkers and reagents for improved disease detection, monitoring, and personalized treatment. Additionally, automated platforms have streamlined laboratory processes, enhanced efficiency, and reduced turnaround times. The convergence of nanotechnology and immunodiagnostics has led to innovative biosensors capable of detecting minute biomolecular interactions with heightened sensitivity. Japan’s dedication to innovationand robust regulatory framework continue to drive the evolution of immunodiagnostic technologies, ultimately enhancing patient care through early and precise disease diagnosis.

In December 2022, bioMérieux unveiled the CE-mark approval for VIDAS KUBE, the advanced automated immunoassay system designed for the VIDAS product line.

Introduction of Latest Technologies

Japan is at the forefront of introducing cutting-edge technologies in vitro diagnostics (IVD). The nation’s innovation landscape showcases remarkable advancements such as microfluidic lab-on-a-chip systems, enabling rapid and accurate biomarker analysis with minimal sample volumes. Next-generation sequencing (NGS) applications have also gained traction, revolutionizing genetic and genomic testing by offering comprehensive insights into diseases. AI-driven diagnostic algorithms enhance precision and speed, aiding in early disease detection and personalized treatment strategies. Additionally, Japan has embraced point-of-care testing (POCT) devices that facilitate on-the-spot medical assessments, which are crucial for remote and resource-limited settings. These technologies not only bolster the efficiency of healthcare delivery but also contribute significantly to Japan’s position as a global leader in IVD innovation.

DiaCarta Inc., a molecular diagnostics company, declared in July 2022 that it had been granted the CE-IVD Mark for its recently developed QuantiVirus SARS-CoV-2 & Flu A/B test.

Enhanced Progress through Key Player Collaboration

The Japan in vitro diagnostics market experienced remarkable progress by fostering collaboration among key industry players. Manufacturers, researchers, and regulatory bodies collectively drove innovation, streamlined regulatory processes, and expedited product development by pooling resources, knowledge, and expertise. Collaborative efforts led to the creation of advanced diagnostic technologies, such as point-of-care testing and personalized medicine solutions, thus addressing Japan’s evolving healthcare needs. Sharing data and best practices improved diagnostic accuracy and accelerated the availability of cutting-edge tests for various diseases. Moreover, collaboration aided in aligning industry practices with regulatory requirements, ensuring timely market access for novel diagnostics.

In July 2021, Sysmex Corporation established a worldwide strategic partnership with QIAGEN N.V to collaborate on the advancement of cancer companion diagnostics.

Rise in Infectious Diseases

In Japan in vitro diagnostics market has witnessed a concerning surge in infectious diseases, prompting a heightened focus on in vitro diagnostics. This upswing can be attributed to increased global travel, urbanization, and evolving pathogens. In response, the Japanese healthcare system has intensified its reliance on in vitro diagnostics to identify infectious agents accurately and swiftly. These diagnostic tools encompass a range of technologies, including molecular assays, immunoassays, and nucleic acid testing, enabling healthcare professionals to diagnose infections and initiate appropriate treatments promptly. This emphasis on advanced diagnostics not only aids in efficient disease management but also plays a pivotal role in containing outbreaks and preventing their spread. As Japan grapples with the complexities of emerging infectious diseases, robust in vitro diagnostics serve as a cornerstone of its strategy to safeguard public health.

In April 2023, Oxford Nanopore Technologies plc and bioMerieux SA joined forces to improve global health results by investigating specific possibilities for introducing nanopore sequencing to infectious disease diagnostics.

Impact of COVID-19

As of March 23, 2022, more than 6.15 million individuals in Japan have been affected by the COVID-19 illness, with a corresponding death toll of 27,246. Throughout 2020, the growth of the Japan IVD (In Vitro Diagnostics) market was impeded by the COVID-19 pandemic, causing delays in routine procedures due to social constraints and precautionary measures. Nevertheless, with the gradual relaxation of social restrictions by governments, the downward trajectory in business revenues began to stabilize and reach a plateau before the onset of the third quarter in 2020. The global landscape remains overshadowed by the looming menace of novel coronavirus, wreaking havoc in the lives of countless individuals. Essential strategies for curbing its impact involve extensive testing and swift hospitalization to mitigate its spread. In this context, in-vitro diagnostics emerge as a pivotal element in ramping up testing efforts. Stakeholders within the in-vitro diagnostic market are diligently working on innovating novel technologies that enable widespread testing within a condensed timeframe.

As an example, during April 2021, Sysmex Corporation secured approval for in vitro diagnostics in Japan, enabling them to manufacture and market the Detect Amp SARS-CoV-2 RT-PCR Kit. This kit is designed to identify the RNA of the novel coronavirus (SARS-CoV-2), which is responsible for COVID-19.

Download Free Sample Report

Report Scope

“Japan In Vitro Diagnostics Market Assessment, Opportunities and Forecast, FY2017-FY2031”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative & quantitative assessment of the current state of the In Vitro Diagnostics market, industry dynamics and challenges. The report includes market size, segmental shares, growth trends, COVID-19, opportunities and forecast between FY2024 and FY2031. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

Click here for full report- https://www.marketsandata.com/industry-reports/japan-in-vitro-diagnostics-market

Latest reports-

Contact

Mr. Vivek Gupta 5741 Cleveland street, Suite 120, VA beach, VA, USA 23462 Tel: +1 (757) 343–3258 Email: info@marketsandata.com Website: https://www.marketsandata.com

[market-insider]

Immunoprotein Diagnostic Testing Market Analysis: Comprehensive Overview of Market Size, Share, Growth

The global immunoprotein diagnostic testing market size is estimated to reach USD 14.86 billion in 2030 and is projected to grow at a CAGR of 7.7% from 2024 to 2030. This growth can be attributed to the rising incidence of chronic diseases. According to American Heart Association’s 2017 statistics, nearly 790,000 people experience heart attack every year in the U.S. In addition, stroke is responsible for 1 in every 20 deaths in the U.S. Hence, WHO is also taking initiatives to reduce the risk of cardiovascular diseases. As a result of the aforementioned factors, the demand for immunoprotein diagnostics is expected to rise in order to facilitate rapid diagnosis.

Immunoprotein Diagnostic Testing Market Report Highlights

Infectious disease testing held largest market share in 2023 owing to the increasing prevalence of infectious diseases and high applications of immunoprotein tests

Enzyme-based immunoassays dominated the market in 2023 due to their frequent usage and availability of large number of products that possess this technology

Chemiluminescence assay is anticipated to witness highest growth over the forecast period due to its high sensitivity and specificity

North America dominated the market in 2023 due to rising prevalence of cancer & increase in mortality due to cancer-related diseases and favorable healthcare reimbursement scenario in the U.S.

For More Details or Sample Copy please visit link @: Immunoprotein Diagnostic Testing Market Report

According to WHO, nearly 1.69 million deaths due to lung cancer were registered in 2015 throughout the world. Hence, fast and accurate diagnosis of such chronic diseases has become important to reduce the high mortality rate. Immunoprotein diagnostic devices and reagents have proved to be highly effective in rapidly detecting chronic diseases.

Technological advancements in the field of immunoprotein diagnostics have led to introduction of novel products. For instance, LIAISON XL, manufactured by DiaSorin, is a fully automated chemiluminescence analyzer that facilitates complete sample processing. It also measures and evaluates testing samples, thereby, enhancing the efficiency and throughput of the system.

List of major companies in the Immunoprotein Diagnostic Testing Market

Agilent Technologies, Inc.

Danaher Corporation

Thermo Fisher Scientific Inc.

PerkinElmer Inc.

Bio-Rad Laboratories, Inc.

Aurora Biomed Inc.

Tecan Trading AG

Promega Corporation

Charles River Laboratories

Creative Biolabs.

For Customized reports or Special Pricing please visit @: Immunoprotein Diagnostic Testing Market Analysis Report

We have segmented the global immunoprotein diagnostic testing market report based on test, technology, material, fluid, application and region.

[industrynewsupdates]

In Vitro Diagnostics Market Size and Regional Outlook Analysis 2024 - 2030

The global in vitro diagnostics market size is expected to reach USD 101.58 billion by 2030, according to a new report by Grand View Research, Inc. It is estimated to register a CAGR of 4.4% over the forecast period driven by the increasing geriatric population, COVID-19 pandemic, and technological advancements in diagnostics that are supporting its adoption. Technological advancements in terms of portability, accuracy, and cost-effectiveness are projected to be one of the high-impact rendering drivers. Technological advancements were further accelerated by the launch of COVID-19 IVD diagnostics and enhanced the adoption of instruments and consumables for technologies, such as PCR. Competitors in the market are increasingly adopting agreement and partnership strategies to maintain a constant flow of business for manufacturers & diagnostics for users.

These agreements are also a result of the harsh price containment strategies for government laboratories, which lowers the price in government settings. For instance, in April 2021, the Italian subsidiary of Seegene, Inc. received a USD 108.25 million tenders for public procurement for the supply of extraction reagents, as well as 7.15 million SARS-CoV-2 diagnostic tests. However, it increases the multiparty nature and complexity of the supply chain. The high prevalence of cancer and Cardiovascular Diseases (CVDs) globally is anticipated to drive diagnostic innovation to facilitate early diagnosis and meet the constantly evolving needs of consumers. Novel technologies, such as plasmonic PCR, are anticipated to commercially enter the market during the forecast period, influencing the business of existing products adversely.

Gather more insights about the market drivers, restrains and growth of the In Vitro Diagnostics Market

Detailed Segmentation:

Market Characteristics

Market growth stage is medium, and the pace of the market growth is decelerating. Decreasing demand for COVID-19 tests is hampering the growth. The market is characterized by a high degree of innovation owing to the increasing introduction of novel molecular diagnostics and immunoassay tests for multiple disease indications. Moreover, increasing demand for patient-centric tests is encouraging market players to develop technologically advanced products.

Product Insights

The reagents segment held the largest share of 65.88% of the overall revenue in 2023. The segment is expected to retain its dominance growing at the fastest CAGR from 2024 to 2030 owing to the extensive R&D initiatives undertaken by major players to develop novel reagents and test kits. For instance, in February 2023, BD received the market approval for the BD Onclarity HPV Assay to be used with the ThinPrep Pap Test in the U.S. The increasing R&D activities to enable faster cancer detection and precision medicine are allowing companies to focus on niche profitable areas in the IVD business. For instance, in March 2023, QIAGEN partnered with Servier to develop a companion diagnostic test for TIBSOVO, indicated for treating the blood cancer acute myeloid leukemia.

Technology Insights

The immunoassay segment accounted for the largest revenue share in 2023. Increasing incidence of chronic & communicable diseases and rising need for early diagnosis are among the key factors leading to an increase in demand for immunological methods, including different types of Enzyme-Linked Immunosorbent Assays (ELISAs). Moreover, key players are focused on R&D pertaining to development of new immunological diagnostic instruments and tests for IVD applications. For instance, in October 2023, Sysmex Corporation and Fujirebio Holdings, Inc. collaborated to enhance their R&D, production, clinical development, and marketing activities in immunoassay.

End-use Insights

The hospitals segment held the largest revenue share in 2023 owing to a rise in the rate of hospitalizations that require support from faster diagnostics. Moreover, the ongoing development of healthcare infrastructure and favorable initiatives taken by government bodies are anticipated to enhance the existing hospital facilities. Thus, the demand for hospital-based IVD tests is increasing. Most IVD devices are purchased by hospitals and used in significant volumes. In 2023, there are over 6,129 hospitals in the U.S. that require constant aid from IVD for critical decision-making, as IVD tests provide faster and more accurate results.

Test Location Insights

The others (lab-based tests) segment accounted for the largest revenue share in 2023. A large number of test analyses at one time and the higher accuracy of laboratory-based tests make them more reliable compared to PoC and home tests, giving segment a competitive edge over the other two segments. Moreover, the availability of tests that allow for sample collection at home and sending it to the laboratories for testing makes testing highly convenient for patients.

Application Insights

The infectious diseases segment dominated the market in 2023. The outbreak of the COVID-19 pandemic increased the segment share significantly in recent years. Moreover, key players are introducing novel testing products to improve access to high-quality, innovative laboratory services for patients & healthcare providers. For instance, in February 2023, BD received EUA from the U.S. FDA for a new molecular diagnostic combination test for SARS-CoV-2, Influenza A+B, and Respiratory Syncytial Virus (RSV). Such initiatives by key players to strengthen their presence are expected to drive market growth.

Regional Insights

North America dominated the market and accounted for a share of 42.28% in 2023. The region is estimated to retain its leading market position throughout the forecast period. The market in this region is collectively driven by factors, such as the rising incidence of chronic diseases, presence of strong players, increasing number of novel test launches, and supportive government funding. For instance, in January 2023, BD and CerTest Biotec received EUA from the U.S. FDA for a PCR test for Mpox virus detection in the U.S. Moreover, the increasing requirement for genetic testing for personalized health care, such as that for diabetes and cancer, is expected to drive market growth in North America.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The global hepatitis diagnostic market size was valued at USD 3.82 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030.

• The global hematology diagnostics market size was valued at USD 7.54 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030. 

Key Companies & Market Share Insights

Some of the key players operating in the in vitro diagnostics market include F. Hoffmann-La Roche Ltd.; Abbott; Quest Diagnostics Inc.; and Danaher. Market players are adopting various strategies, such as new product launches, mergers & acquisitions, and partnerships, to strengthen their product portfolios and offer diverse technologically advanced & innovative products.

Key In Vitro Diagnostics (IVD) Companies:

• Abbott

• bioMérieux SA

• QuidelOrtho Corporation

• Siemens Healthineers AG

• Bio-Rad Laboratories, Inc.

• Qiagen

• Sysmex Corporation

• Charles River Laboratories

• Quest Diagnostics Incorporated

• Agilent Technologies, Inc.

• Danaher Corporation

• BD

• F. Hoffmann-La Roche Ltd.

In Vitro Diagnostics Market Segmentation

Grand View Research has segmented the global in vitro diagnostics (IVD) market report based on product, technology, application, end-use, test location, and region:

IVD Product Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Reagents

• Services

IVD Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Immunoassay

o Instruments

o Reagents

o Services

• Hematology

o Instruments

o Reagents

o Services

• Clinical Chemistry

o Instruments

o Reagents

o Services

• Molecular Diagnostics

o Instruments

o Reagents

o Services

• Coagulation

o Instruments

o Reagents

o Services

• Microbiology

o Instruments

o Reagents

o Services

• Others

o Instruments

o Reagents

o Services

IVD Application Outlook (Revenue, USD Million, 2018 - 2030)

• Infectious Diseases

• Diabetes

• Oncology

• Cardiology

• Nephrology

• Autoimmune Diseases

• Drug Testing

• Others

IVD Test Location Outlook (Revenue, USD Million, 2018 - 2030)

• Point of Care

• Home-care

• Others

IVD End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals

• Laboratory

• Home-care

• Others

IVD Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Spain

o Italy

o Russia

o Denmark

o Sweden

o Norway

• Asia Pacific

o Japan

o China

o India

o South Korea

o Australia

o Thailand

o Singapore

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa (MEA)

o South Africa

o Saudi Arabia

o UAE

o Kuwait

Order a free sample PDF of the In Vitro Diagnostics Market Intelligence Study, published by Grand View Research.

Recent Developments

• In December 2023, ARUP Laboratories and Medicover collaborated to provide diagnostic and healthcare services in Europe. ARUP Laboratories has developed AAV5 DetectCDx in collaboration with BioMarin Pharmaceutical Inc. to select therapies for severe hemophilia A patients

• In November 2023, Veracyte joined Illumina to develop molecular tests for decentralized IVD applications. Companies are focusing on the development of Prosigna breast cancer and Percepta nasal swab tests of Veracyte

• In October 2023, Promega Corporation announced its plan to develop and commercialize companion diagnostics kits with GSK Plc to identify cancer patients with MSI-H solid tumors

• In February 2023, Unilabs announced investing over USD 200 million in Siemens Healthineers' technology and acquiring more than 400 laboratory analyzers to strengthen its laboratory infrastructure

• In February 2023, F. Hoffmann-La Roche Ltd. collaborated with Janssen Biotech Inc. to develop companion diagnostics for targeted therapies. Companion diagnostic technologies include digital pathology, NGS, PCR, immunoassays, and immunohistochemistry

[credenceresearchdotblog]

The Carcinoembryonic Antigen Market is projected to grow from USD 1235 million in 2024 to an estimated USD 3522.944 million by 2032, with a compound annual growth rate (CAGR) of 14% from 2024 to 2032.The global Carcinoembryonic Antigen (CEA) market has been experiencing significant growth, driven by advancements in cancer diagnostics, increased prevalence of cancer worldwide, and the growing awareness of the role of biomarkers in early cancer detection. CEA is a glycoprotein involved in cell adhesion and is commonly used as a tumor marker in cancer diagnostics, particularly for colorectal cancer. This article provides an in-depth analysis of the CEA market, exploring key drivers, restraints, opportunities, and trends shaping its future trajectory.

Browse the full report at https://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-market

Market Definition and Scope

Carcinoembryonic Antigen (CEA) is a biomarker that is frequently measured in blood samples to monitor cancer progression, especially in patients with colorectal, breast, pancreatic, and lung cancers. CEA levels can provide essential insights into cancer recurrence, response to therapy, and prognosis. It plays a crucial role in detecting cancer at an early stage, allowing for timely intervention and personalized treatment plans. The global CEA market encompasses various diagnostic tests, including CEA assays, kits, reagents, and instrumentation.

Key Drivers of the CEA Market

1. Rising Prevalence of Cancer: The increasing incidence of cancer globally is one of the primary factors driving the CEA market. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, accounting for approximately 10 million deaths in 2020. Colorectal cancer, in particular, is among the most common cancers, and CEA is widely used in its diagnosis and management.

2. Advancements in Diagnostic Technologies: Technological advancements in diagnostic tools and techniques have improved the accuracy and efficiency of CEA testing. The introduction of highly sensitive immunoassays, such as enzyme-linked immunosorbent assays (ELISAs) and chemiluminescence immunoassays (CLIAs), has enhanced the ability to detect CEA levels in patients, contributing to better cancer management.

3. Growing Demand for Personalized Medicine: As the healthcare industry shifts towards personalized medicine, the demand for biomarkers like CEA is increasing. CEA testing helps in tailoring treatment strategies based on an individual’s tumor biology and response to therapy, improving treatment outcomes and reducing adverse effects.

4. Increasing Awareness and Government Initiatives: Governments and healthcare organizations worldwide are raising awareness about cancer prevention and early detection. In many countries, cancer screening programs that include CEA testing are being implemented to identify high-risk populations. This has further propelled the demand for CEA diagnostic tests.

Challenges and Restraints

1. Limited Specificity of CEA Testing: One of the primary limitations of CEA as a biomarker is its lack of specificity. Elevated CEA levels can also be observed in non-cancerous conditions such as smoking, liver disease, and inflammatory conditions. This can lead to false-positive results, complicating the diagnostic process. Consequently, CEA testing is often used in conjunction with other diagnostic tools to improve accuracy.

2. High Cost of Advanced Diagnostic Tools: The cost associated with advanced diagnostic technologies, including CEA assays, can be prohibitive for healthcare providers, especially in low- and middle-income countries. This limits the accessibility of CEA testing in certain regions, thereby restricting market growth.

3. Regulatory and Reimbursement Challenges: Regulatory approval processes and reimbursement policies for diagnostic tests vary significantly across regions. Stringent regulations and the absence of uniform reimbursement policies can hinder market growth, particularly for new entrants.

Opportunities in the CEA Market

1. Emerging Markets: Developing countries, particularly in Asia-Pacific, are witnessing a surge in healthcare infrastructure development and cancer awareness programs. These regions present significant opportunities for market expansion as healthcare providers invest in advanced diagnostic tools, including CEA testing.

2. Integration of Artificial Intelligence (AI): The integration of AI and machine learning in diagnostic tools offers promising opportunities for the CEA market. AI-powered algorithms can enhance the interpretation of CEA test results, leading to more accurate and timely diagnoses.

3. Collaboration Between Key Players: Collaborations between pharmaceutical companies, diagnostic laboratories, and research institutions can accelerate the development of innovative CEA tests and assays. Such partnerships can also help in overcoming challenges related to regulatory approvals and market penetration.

Market Segmentation

The CEA market can be segmented based on product type, application, and end-user. Product types include CEA assays, kits, reagents, and instruments. Applications of CEA testing are primarily in colorectal cancer, followed by breast, pancreatic, and lung cancers. Key end-users of CEA testing products are hospitals, diagnostic laboratories, and research institutions.

Competitive Landscape

Several key players dominate the CEA market, including Abbott Laboratories, F. Hoffmann-La Roche AG, Siemens Healthineers, and Thermo Fisher Scientific. These companies focus on product innovation, partnerships, and geographic expansion to maintain a competitive edge. For instance, Roche’s Elecsys CEA assay is a popular product in cancer diagnostics, offering high precision and reliability.

Key Player Analysis:

Abbott (U.S.)

Aviva Systems Biology Corporation

Boster Biological Technology (U.S.)

Cigna (U.S.)

Correlogic Systems, Inc. (Hong Kong)

Creative Diagnostics (U.S.)

Hoffmann-La Roche Ltd (Switzerland)

Genway Biotech, LLC. (U.S.)

Laboratory Corporation of America Holdings (U.S.)

Lee BioSolutions (U.S.)

Mayo Foundation for Medical Education and Research (MFMER) (U.S.)

Merck KGaA (Germany)

Omega Diagnostics Group PLC (U.K.)

Prospec-Tany Technogene Ltd (Israel)

Quest Diagnostics Incorporated (U.S.)

RayBiotech Life, Inc (U.S.)

Segmentation:

By Type,

Serum CEA

Tissue CEA.

By Gender,

Male

Female

By Product,

Kits,

Reagents,

Instruments

By Test,

Clinical testing

Research testing.

By End-Use,

Hospitals,

Diagnostic laboratories,

Research institutes.

By  Region

North America

The U.S

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[tamanna31]

Blood Screening Market 2023- Business Planning Research and Resources, Revenue, and Forecasts 2030

Blood Screening Market Size & Trends

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

Nucleic Acid Amplification Test (NAT)

ELISA

Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

Next Generation Sequencing

Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagent

Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

Sweden

Norway

Denmark

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[amrutatbrc1]

Coagulation Markers Market By Product Type, By Manufacturers, By End-User And Market Trend Analysis Forecast 2033

The Coagulation Markers Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Coagulation Markers Market: https://www.thebusinessresearchcompany.com/report/coagulation-markers-global-market-report

According to The Business Research Company’s Coagulation Markers Global Market Report 2024, The coagulation markers market size is expected to see strong growth in the next few years. It will grow to $1.52 billion in 2028 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to a growing incidence of chronic diseases, rising adoption of personalized medicine, a growing global population, rising healthcare expenditures, and expansion in emerging markets. Major trends in the forecast period include the integration of AI and machine learning, the development of novel biomarkers, enhanced point-of-care technologies, automation in laboratories, wearable health technologies, telehealth and remote monitoring, and sustainable diagnostic practices.

The rise in the prevalence of blood disorders is expected to propel the growth of the coagulation markers market going forward. Blood disorders refer to a wide range of conditions that affect the blood's ability to function correctly. The prevalence of blood disorders is growing due to aging populations, increased awareness, and improved diagnostic capabilities. Coagulation markers help diagnose and manage blood disorders by assessing clotting function, identifying abnormalities, and monitoring treatment effectiveness for conditions like hemophilia and thrombosis. For instance, in May 2024, according to the Leukaemia Foundation, an Australia-based non-profit organization, currently around 135,000 people in Australia are living with a blood cancer or blood disorder, with this number projected to exceed 275,000 by 2035. Therefore, an increasing prevalence of blood disorders is driving the coagulation marker market.

Get A Free Sample Of The Report (Includes Graphs And Tables): https://www.thebusinessresearchcompany.com/sample.aspx?id=17117&type=smp

The coagulation markers market covered in this report is segmented –

1) By Product: D-Dimer Assay, Fibrinogen Assay 2) By Sample Type: Plasma, Whole Blood Sample, Other Sample Types 3) By Technology: Fluorescence Immunoassay, Enzyme-Linked Immuno Sorbent Assay (ELISA), Rapid Test, Particle Enhanced Immunoturbidimetric Assay 4) By Application: Deep Venous Thrombosis (DVT), Pulmonary Embolism (PE), Disseminated Intravascular Coagulation (DIC), Trauma, Other Applications 5) By End User: Hospital, Specialty Clinics, Academic And Research Institute, Diagnostics Laboratories

Major companies operating in the coagulation markers market are focusing on developing technologically innovative solutions, such as automated blood coagulation analyzers, to improve diagnostic accuracy, enhance efficiency, and provide faster results for better patient management. An automated blood coagulation analyzer is a medical device that automatically performs various tests to evaluate blood clotting function, providing rapid and accurate results for diagnosing and managing coagulation disorders. For instance, in July 2021, Sysmex Corporation, a Japan-based provider of in-vitro diagnostic solutions, announced the launch of its new automated blood coagulation analyzers named CN-6000 and CS-5100, designed to provide efficient and accurate coagulation testing in clinical laboratories. The CN-6000 is a fully automated coagulation analyzer with a maximum throughput of 240 tests per hour, featuring automatic sample pre-treatment, clot detection, and quality control management. The CS-5100, on the other hand, is a compact and versatile coagulation analyzer suitable for small to medium-sized laboratories, offering a throughput of up to 120 tests per hour and a user-friendly interface. Both analyzers support a wide range of coagulation assays and are designed to streamline coagulation testing workflows, improve turnaround times, and enhance patient care in clinical laboratories.

The coagulation markers market report table of contents includes:

1. Executive Summary 

2. Coagulation Markers Market Characteristics

3. Coagulation Markers Market Trends And Strategies

4. Coagulation Markers Market - Macro Economic Scenario

5. Global Coagulation Markers Market Size and Growth ............

32. Global Coagulation Markers Market Competitive Benchmarking

33. Global Coagulation Markers Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Coagulation Markers Market

35. Coagulation Markers Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[businessindustry]

Chemiluminescence Immunoassay (CLIA) Market Application, CAGR Status, Growth 2024-2032

The Reports and Insights, a leading market research company, has recently releases report titled “Chemiluminescence Immunoassay (CLIA) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032.” The study provides a detailed analysis of the industry, including the global Chemiluminescence Immunoassay (CLIA) Market share, size, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the Chemiluminescence Immunoassay (CLIA) Market?

As per Reports and Insights Analysis, the chemiluminescence immunoassay (CLIA) market is expected to grow at a CAGR of 7.8% during the forecast period of 2024 to 2032.

What are Chemiluminescence Immunoassay (CLIA)?

Chemiluminescence immunoassay (CLIA) is a highly sensitive laboratory technique used to identify specific proteins or substances in a sample, such as hormones, antibodies, or antigens. It relies on chemiluminescence, a process where a chemical reaction produces light. In CLIA, this reaction occurs when a labeled molecule, like an enzyme or a fluorophore, attached to an antibody or antigen binds to the target substance. The emitted light is then measured by a sensitive detector, with the intensity of the light directly proportional to the amount of the target substance in the sample. Due to its high sensitivity and specificity, CLIA is extensively used in clinical laboratories for disease diagnosis, therapeutic drug monitoring, and research purposes.

Request for a sample copy with detail analysis: https://www.reportsandinsights.com/sample-request/1671

What are the growth prospects and trends in the Chemiluminescence Immunoassay (CLIA) industry?

The chemiluminescence immunoassay (CLIA) market growth is driven by various factors. The market for chemiluminescence immunoassays (CLIA) is experiencing notable growth, fueled by increasing demand for precise and sensitive diagnostic tests. CLIA's advantages include high sensitivity, a broad dynamic range, and excellent specificity, making it well-suited for detecting various biomarkers in clinical diagnostics and research. Factors such as the rising prevalence of chronic and infectious diseases, a growing elderly population, and increased demand for quick and dependable diagnostic tests are propelling market expansion. Furthermore, technological advancements, like automated CLIA systems, are also contributing to market growth. Hence, all these factors contribute to chemiluminescence immunoassay (CLIA) market growth.

What is included in market segmentation?

The report has segmented the market into the following categories:

By Product Type:

Analyzers

Reagents & Consumables

By Analyzer Type:

Benchtop Analyzers

Floor-standing Analyzers

By Application:

Infectious Diseases

Oncology

Cardiology

Autoimmune Diseases

Others

By End-Use:

Hospitals & Diagnostic Laboratories

Research & Academic Institutes

Pharmaceutical & Biotechnology Companies

Contract Research Organizations (CROs)

Segmentation By Region:

North America:

United States

Canada

Asia Pacific:

China

India

Japan

Australia & New Zealand

Association of Southeast Asian Nations (ASEAN)

Rest of Asia Pacific

Europe:

Germany

The U.K.

France

Spain

Italy

Russia

Poland

BENELUX (Belgium, the Netherlands, Luxembourg)

NORDIC (Norway, Sweden, Finland, Denmark)

Rest of Europ

Latin America:

Brazil

Mexico

Argentina

Rest of Latin America

The Middle East & Africa:

Saudi Arabia

United Arab Emirates

South Africa

Egypt

Israel

Rest of MEA (Middle East & Africa)

Who are the key players operating in the industry?

The report covers the major market players including:

Roche Diagnostics

Siemens Healthineers

Abbott Laboratories

Beckman Coulter (a subsidiary of Danaher Corporation)

Ortho Clinical Diagnostics

bioMérieux SA

DiaSorin S.p.A.

Sysmex Corporation

Thermo Fisher Scientific Inc.

Mindray Bio-Medical Electronics Co., Ltd.

Randox Laboratories Ltd.

Snibe Diagnostic

View Full Report: https://www.reportsandinsights.com/report/Chemiluminescence Immunoassay (CLIA)-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

Reports and Insights consistently mееt international benchmarks in the market research industry and maintain a kееn focus on providing only the highest quality of reports and analysis outlooks across markets, industries, domains, sectors, and verticals. We have bееn catering to varying market nееds and do not compromise on quality and research efforts in our objective to deliver only the very best to our clients globally.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

Reports and Insights Business Research Pvt. Ltd. 1820 Avenue M, Brooklyn, NY, 11230, United States Contact No: +1-(347)-748-1518 Email: sales@reportsandinsights.com Website: https://www.reportsandinsights.com/ Follow us on LinkedIn: https://www.linkedin.com/company/report-and-insights/ Follow us on twitter: https://twitter.com/ReportsandInsi1

[123567-9qaaq9]

Protein Production Technologies Outlines, Future Trends, Insight And Quality Analysis 

Protein production technologies represent the backbone of modern biotechnology, driving innovation across multiple industries including pharmaceuticals, agriculture, and biomanufacturing. . 

The Protein Production Technologies  was valued at $2,393.0 million in 2023 and is expected to reach $6,963.6 million by 2033, growing at a CAGR of 11.27% between 2023 and 2033

Gene Expression Analysis Overview 

Protein production technologies encompass a diverse array of methodologies, tools, and techniques utilized to generate proteins for various applications in research, medicine, industry, and beyond. These technologies are designed to efficiently produce recombinant proteins, peptides, and other biomolecules, either in living organisms (in vivo) or in laboratory settings (in vitro).

In vivo protein production technologies typically involve genetically engineering host organisms, such as bacteria, yeast, insect cells, or mammalian cells, to express specific proteins of interest. This can be achieved through the use of expression vectors containing the gene encoding the target protein, along with regulatory elements to drive its expression.

Market Segmentation

Segmentation 1: By Application

Segmentation 2: By End User 

Segmentation 3: By Product

Segmentation 4: By Expression System

Segmentation 5: By Region

Protein expression in North America is a dynamic and crucial field with a significant impact across industries. 

The region, especially North America, is a global leader in biopharmaceuticals, relying extensively on protein expression for producing biologics, including monoclonal antibodies and vaccines. 

North America holds the largest share of the Protein Production Technologies 

Download our sample page now click here !

Application for  Recombinant Protein Production Technologies  

Drug Discovery 

Structural Biology 

Disease Modelling 

Enzyme Production 

Vaccines Development 

Therapeutic Proteins 

Immunoassays 

Key Market Players 

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

Charles River Laboratories International, Inc.

Danaher Corporation (Abcam plc.)

GenCefe Co., Ltd.

Genscript Biotech Corporation

And many others 

Market Dynamics

Market Drivers 

Increasing Demand for Protein Biologics Creating the Need for Protein Expression 

Market Restraints 

Long and Complicated Regulatory Timelines and Approvals of Recombinant Proteins and Biologics

Market Opportunities 

Rising Awareness of Proteomics in Emerging Countries 

 Visit our Life Sciences & Biopharma page for better understanding 

Key factors contributing to the growth of the recombinant Protein Production Technologies  

Expanding applications of recombinant proteins in drug discovery, biomanufacturing, and diagnostic assays

Rising prevalence of chronic diseases and the need for innovative therapies.

Recent Developments in the Recombinant Protein Production Technologies 

In January 2024, Evosep, a leader in sample preparation for mass spectrometry-based proteomics, partnered with Thermo Fisher Scientific Inc., a global scientific leader, to advance clinical proteomics research. This collaboration would combine Evosep's sample separation technology with Thermo Fisher Scientific Inc.'s mass spectrometry instruments, enhancing proteomics research capabilities.release would support pharmaceutical and biotechnology companies engaged in the manufacturing of therapeutic proteins, with the goal of improving product quality and expediting time-to-market.

Key Questions Answered 

Q What is the estimated global market size for the Protein Production Technologies ?

Q What are the future trends expected in the Protein Production Technologies ?

Q What does the supply chain and value chain of the Protein Production Technologies  look like?

Q  What is the regulatory framework of the Protein Production Technologies ?

Q How has the COVID-19 outbreak affected the future trajectory of the Protein Production Technologies ?

Q What are the market entry barriers and opportunities in the Protein Production Technologies ?

Q What are the major market drivers, challenges, and opportunities of the Protein Production Technologies ?

Q How is each segment of the Protein Production Technologies  expected to grow during the forecast period, and what is the anticipated revenue generated by each of the segments by the end of 2033?

Q What is the growth potential of the global Protein Production Technologies  in North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World, and what are the driving and challenging factors of the market in each of these regions?

Q Who are the leading players with significant offerings in the Protein Production Technologies , and what is the current market dominance for each of these leading players? Who are the next frontiers in the Protein Production Technologies ?

Conclusion 

In conclusion, the Protein Production Technologies  continues to thrive and evolve as a vital component of numerous industries, including biotechnology, pharmaceuticals, agriculture, and research

[globalinsightsservices]

Esoteric Testing Market to Witness Growth Acceleration During 2021-2033

Market Definition

Esoteric Testing involves the laboratory examination of uncommon molecules and substances that is not often done in a clinical laboratory. These tests are carried out when a doctor needs more comprehensive information regarding the patient’s health. To assess the outcome, a sophisticated device, materials, and specialist are needed.

Market Dynamics

The global esoteric testing market was valued at USD 21.4 billion in 2022 and it is anticipated to grow further up to USD 62.9 billion by 2032, at a CAGR of 11.4% during the forecast period.

To Know More@ https://www.globalinsightservices.com/reports/esoteric-testing-market/

Market Trends and Drivers

The growing geriatric population coupled with the increasing prevalence of chronic and infectious diseases and advancing esoteric DNA sequencing technologies in precision medicine, early diagnosis of cancer, and precision medicine are boosting the growth of the market. Globally, chronic diseases including diabetes, heart disease, and cancer are on the rise. Infectious disease prevalence is also rising at an alarming rate and includes diseases like Dengue, Hepatitis B, C, HIV, Malaria, Tuberculosis, and others. The knowledge of esoteric testing for the quick and accurate detection of certain disorders is growing. Esoteric tests’ improving technology is providing quicker results with improved sensitivity, detection limits, and efficacy. The market is expanding as a result of the rising use of esoteric DNA sequencing, NGS technologies, and whole genome sequencing in the early diagnosis of cancer, precision medicine, and personalized medicine.

Request Sample@ https://www.globalinsightservices.com/request-sample/GIS10283/?utm_id=1017

Research Objectives

Estimates and forecast the overall market size for the total market, across product, service type, type, end-user, and region

Detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling

Identify factors influencing market growth and challenges, opportunities, drivers and restraints

Identify factors that could limit company participation in identified international markets to help properly calibrate market share expectations and growth rates

Trace and evaluate key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities

Thoroughly analyze smaller market segments strategically, focusing on their potential, individual patterns of growth, and impact on the overall market

To thoroughly outline the competitive landscape within the market, including an assessment of business and corporate strategies, aimed at monitoring and dissecting competitive advancements.

Identify the primary market participants, based on their business objectives, regional footprint, product offerings, and strategic initiatives

Request Customization@ https://www.globalinsightservices.com/request-customization/GIS10283/

Global Esoteric Testing Market Segmentation:

By Type

Infectious Diseases Testing

Endocrinology Testing

Oncology Testing

Genetics Testing

Toxicology Testing

Immunology Testing

Neurology Testing

Others

By Technology

Chemiluminescence Immunoassay

Enzyme-Linked Immunosorbent Assay

Mass Spectrometry

Real-Time PCR

DNA Sequencing

Flow Cytometry

Others

By End User

Independent & Reference Laboratories

Hospital Based Technologies

Research Scope

Scope – Highlights, Trends, Insights. Attractiveness, Forecast

Market Sizing – Product Type, End User, Offering Type, Technology, Region, Country, Others

Market Dynamics – Market Segmentation, Demand and Supply, Bargaining Power of Buyers and Sellers, Drivers, Restraints, Opportunities, Threat Analysis, Impact Analysis, Porters 5 Forces, Ansoff Analysis, Supply Chain

Business Framework – Case Studies, Regulatory Landscape, Pricing, Policies and Regulations, New Product Launches. M&As, Recent Developments

Competitive Landscape – Market Share Analysis, Market Leaders, Emerging Players, Vendor Benchmarking, Developmental Strategy Benchmarking, PESTLE Analysis, Value Chain Analysis

Company Profiles – Overview, Business Segments, Business Performance, Product Offering, Key Developmental Strategies, SWOT Analysis.

Buy your copy here@ https://www.globalinsightservices.com/checkout/single_user/GIS10283/

With Global Insight Services, you receive:

10-year forecast to help you make strategic decisions

In-depth segmentation which can be customized as per your requirements

Free consultation with lead analyst of the report

Infographic excel data pack, easy to analyze big data

Robust and transparent research methodology

Unmatched data quality and after sales service

Contact Us:

Global Insight Services LLC 16192, Coastal Highway, Lewes DE 19958 E-mail: info@globalinsightservices.com Phone: +1-833-761-1700 Website: https://www.globalinsightservices.com/

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

[blog-site-for-market-research]

Understanding Market Dynamics in the Autoimmune Disease Diagnostics Market Industry

Market Overview –

The size of the market for autoimmune disease diagnostics was estimated at USD 4.9 billion in 2022 and is expected to increase at a compound yearly growth rate (CAGR) of 6.7% from USD 5.23 billion in 2023 to USD 8.78 billion by 2032.

The autoimmune disease diagnostics market is witnessing growth driven by advancements in the diagnosis of lupus and other autoimmune conditions. With increasing awareness and understanding of these diseases, there's a rising demand for accurate and efficient diagnostic tools. Innovations in biomarker testing and imaging techniques are enhancing early detection and personalized treatment strategies, driving market expansion.

The autoimmune disease diagnostics market focuses on providing tools and tests for diagnosing autoimmune diseases, a group of conditions where the immune system attacks healthy cells and tissues. These diseases can affect various organs and systems in the body, leading to chronic inflammation, tissue damage, and functional impairment.

Market growth is driven by the increasing prevalence of autoimmune diseases worldwide, attributed to factors such as genetic predisposition, environmental triggers, and lifestyle factors. With millions of people affected by autoimmune diseases, there is a growing demand for accurate and timely diagnostic tests to facilitate early intervention and improve patient outcomes.

Technological advancements and innovations in autoimmune disease diagnostics are shaping the market, offering new biomarkers, imaging techniques, and molecular assays to enhance diagnostic accuracy and precision. From serological tests and genetic testing to advanced imaging modalities and point-of-care devices, these advancements enable healthcare providers to diagnose autoimmune diseases more effectively and tailor treatment strategies to individual patient needs.

Moreover, the growing recognition of the importance of early detection and personalized medicine is driving market growth, as healthcare systems prioritize preventive healthcare and precision diagnostics to improve patient care and reduce healthcare costs.

However, challenges such as variability in disease presentation, overlapping symptoms, and limited awareness among healthcare providers pose obstacles to market growth. Addressing these challenges requires greater education and training for healthcare professionals, improved access to diagnostic tools and resources, and collaboration between industry stakeholders to develop standardized diagnostic protocols and guidelines.

Segmentation –

The global autoimmune disease diagnostics market has been segmented on the basis of disease type, test type, and end-user.

The market, by disease type, has been classified as systemic autoimmune disease, and localized autoimmune disease. The systemic autoimmune disease segment has been further classified into psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus (SLE), and others. Localized autoimmune disease segment has been divided into inflammatory bowel disease, thyroid, type 1 diabetes, and others.

On the basis of test type, the market has been segregated into  western blotting, enzyme-linked immunosorbent assay (ELISA), double immune diffusion, dot blot, counter immune-electrophoresis, line blot, immunofluorescence assays (IFA), multiplex immunoassay, agglutination, and others.

The end-user segment has been divided into, has been segmented into hospitals, diagnostics centers, research laboratories, and others

Regional Analysis –

The autoimmune disease diagnostics market varies regionally due to differences in disease prevalence, diagnostic infrastructure, and healthcare expenditure. Developed regions like North America and Europe have a higher prevalence of autoimmune diseases and well-established diagnostic capabilities, leading to a robust market for autoimmune disease diagnostics. In contrast, developing regions face challenges such as limited access to specialized testing facilities and lower awareness of autoimmune diseases, resulting in underdiagnosis and undertreatment.

Moreover, variations in regulatory frameworks and reimbursement policies influence market dynamics across different regions. As the burden of autoimmune diseases continues to rise globally, there is a growing need for affordable and accessible diagnostic solutions, particularly in underserved regions. Collaborative efforts between healthcare stakeholders and diagnostic companies are essential to address regional disparities and improve patient outcomes in the autoimmune disease diagnostics market.

Key Players –

Autoimmune disease diagnostics companies include Siemens Healthcare Private Limited, bioMérieux SA, Bio-rad Laboratories, Beckman Coulter, AstraZeneca, EUROIMMUN AG, Hoffmann-la Roche, Inova Diagnostics, Myriad Genetics, Thermo Fisher Scientific, Trinity Biotech Plc., and Hemagen Diagnostics.

Related Reports –

Urinalysis Test

Celiac Disease Treatment

Healthcare Enterprise Software

Amniotic Membrane

For more information visit at MarketResearchFuture

[latestindustryreports]

Esoteric Testing Market Industry Growth with Key Manufacturers Analysis

The Insight Partners through the latest research report titled- “ Esoteric Testing Market Statistics and Industry Analysis| 2025” brings to investors, a detailed analysis of the Esoteric Testing market from entrepreneurs’ point of view. Investigation of current market scenarios draws valuable insights for companies.

This study offers indulge into market incentives, challenges, and opportunities that businesses must not miss. As consumer-centric businesses tend to generate greater ROIs, opting for a Esoteric Testing market research would be a business recipe for success. Considering the escalated competition in the Esoteric Testing market, only creating a mere hunch of products won’t be sufficient. Market research can help businesses to predict product potential and success.

What to expect from this edition of Esoteric Testing market report?

1) Analysis of Industry Dynamics

This chapter studies different variables that characterize the Esoteric Testing market such as drivers, restraints, threats, and opportunities. Genuine determinants of markets are fostering innovations. This section focuses on how the activities of businesses are distributed and what factors influence growth. A wide spectrum of Esoteric Testing market-specific data is offered allowing initial determination of market potential.

2) Competitive Comparison Matrix

This chapter in Esoteric Testing market research aims to offer a competitive comparison matrix for companies. This section offers a complete picture of competitors' scale-ups and their business strategies. Businesses can figure out alternatives to competitors through thorough market surveys and target market insights. By learning about competition offerings, companies can discover new market niches and sales funnel. Key companies in the Esoteric Testing market are- .

3) Industry Specific COVID-19 Impact Analysis

The global health epidemic of COVID-19 brought supply demand disruption. Esoteric Testing Market players faced challenges to survive their production lifecycle, reduced revenues, and weak marketing performance. At the same time, companies faced a crunch in distribution channels due to lockdowns and transport restrictions. Small, and medium-sized companies struggled to manage expectations and hold on to supply-demand equilibrium. This section covers the impact analysis of COVID-19 on business and alternative ways used by businesses to respond to the pandemic-led disruptions. Post-Covid -19 recovery prospects are also covered in this chapter.

4) Segmentation of Esoteric Testing Market

In a competitive Esoteric Testing market, learning about key segments is essential for brands to cater to their customers. It is a powerful aspect of market research to streamline market strategies. This section under research highlights segments based on products, applications, and regions. Understanding demographics and high ROI geographical markets helps brands to further optimize their products and services.

Based on Technology of Esoteric Testing Market Research report:

Chemiluminescence Immunoassay

Real-Time PCR

Flow Cytometry

Mass Spectrometry

Enzyme-Linked Immunosorbent Assay

Based on Test Type of Esoteric Testing Market Research report:

Infectious Diseases Testing

Oncology Testing

Genetic Testing

Neurology Testing

Endocrinology Testing

Toxicology Testing

Based on End User of Esoteric Testing Market Research report:

Hospital Laboratories

Independent & Reference Laboratories

Based on Regions:

North America (U.S., Canada, Mexico)

Europe (U.K., France, Germany, Spain, Italy, Central & Eastern Europe, CIS)

Asia Pacific (China, Japan, South Korea, ASEAN, India, Rest of Asia Pacific)

Latin America (Brazil, Rest of Latin America)

The Middle East and Africa (Turkey, GCC, Rest of the Middle East and Africa)

Rest of the World…

Business Takeaways for Esoteric Testing market participants:

Resource planning insights based on value chain analysis

Product positioning strategies for new entrants in Esoteric Testing market

Leading Esoteric Testing market participants and their growth strategies

Market estimated on key geographical markets, leading participants, and product segments.

Detailed analysis of market trends covering the latest innovations.

Details on market dynamics including- market incentives, restraints, threats, and growth opportunities.

[industrynewsupdates]

Nurse Call Systems Market Key Companies, Growth and Forecast Report, 2030

The global nurse call systems market size was valued at USD 1.7 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 12.11% from 2023 to 2030. 

The growing need for a diverse and integrated platform that increases the preference for mobility aids are driving the market. Medicare decides to refund schemes based on quality and outcome rather than quantity owing to the rising healthcare cost. Medicare estimates that current reimbursement practices are costing an additional USD 2.1 billion and expects to curtail this by using technology-focused healthcare. With this change in reimbursement policies, hospitals and other healthcare facilities are trying to streamline their workflow processes by adopting technology-oriented nurse call systems.

Nurse call systems enable reliable and flexible communication between the patient and the caregiver. Increasing patient numbers in healthcare facilities and the introduction of advanced ways to expand communication, workflow, and management to provide quality patient care are fueling the market growth. The market is primarily driven by technological advancements that have allowed players to create innovative devices. For instance, in December 2019, Tunstall Group launched Tunstall Carecom, a wireless and digital nurse call system.

Gather more insights about the market drivers, restrains and growth of the Nurse Call Systems Market

Blood Screening Market Report Highlights

• The reagent segment accounted for the largest revenue share of around 73.0% in 2022 and is expected to grow at the fastest CAGR of 12.0% over the forecast period.

• North America dominated the market and accounted for the largest revenue share of 39.0% in 2022 owing to the presence of key industry players, increased adoption of the blood screening process, stringent FDA regulations for transfusion, rising infectious disease prevalence, and greater patient affordability are responsible for maintaining its position during the forecast period.

• Asia Pacific is expected to grow at the fastest CAGR of 13.5% over the forecast period owing to increasing awareness about blood donation, rising patient affordability, and the focus of key industry players on emerging countries in the region.

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global emergency medical services product market size was valued at USD 22.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.4% from 2024 to 2030.

• The global scanning electron microscopes market size was valued at USD 4.34 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2030. 

Blood Screening Market Segmentation

Grand View Research has segmented the blood screening market by product, technology, and region:

Blood Screening Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Blood Screening Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Blood Screening Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Order a free sample PDF of the Nurse Call Systems Market Intelligence Study, published by Grand View Research.

[delvenservices]

ELISpot and FluoroSpot Assay Market Key Findings & Key Players: 2030

The ELISpot and FluoroSpot Assay Market is Segmented By Product (Analyzers, Assay Kits, and Ancillary Products), Application (Research and Diagnostics), End-User (Hospitals & Clinical Labs, Biopharmaceutical Companies, and Research Institutes) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).

Market Overview

The global ELISpot and FluoroSpot Assay market size was estimated at USD 295.64 million in 2023 and is projected to reach USD 503.41 million in 2030 at a CAGR of 7.9% during the forecast period 2023-2030.

Due to its excellent sensitivity, the enzyme-linked immunospot (ELISpot) test is frequently used to identify different illness conditions. They're incredibly adaptable and frequently employed to gauge antigen-specific T lymphocytes in mice and people. Because they may measure a wide range of immune responses and cellular immune-related activities, these tests are increasingly recommended and well-liked. Thus, ELISpot has now undergone a considerable transformation from a research tool to a clinical test that is often used in laboratories. Several ELISpot tests, including as those for IFN-gamma, Granzyme B, TGF-Beta 1, Fluorescent, and others, are used for a variety of diagnostic purposes. In order to conduct the FluoroSpot test, a 96-well plate containing a combination of monoclonal antibodies and PVDF membranes is used as the assay platform. For secreted proteins like cytokines from active cells, the ELISpot and FluoroSpot are ideally suited.

The worldwide ELISpot and FluoroSpot assay market is divided into infectious illnesses, cancer, autoimmune disorders, allergies, and others on the basis of diseases. The infectious illness is further divided into categories like COVID-19, the flu, HIV, and others. Due to the rising prevalence of chronic infectious illnesses and the higher productivity associated with the use of ELISpot and FluoroSpot tests, the infectious diseases sector is anticipated to dominate the ELISpot and FluoroSpot assay market in 2021. Diagnostic and research applications make up the segments of the global ELISpot and FluoroSpot assay market. Infectious illnesses, transplants, and other conditions are further divided into sub-segments within the diagnostic applications. The research applications are further divided into the following categories: cancer research, clinical trials, vaccine development, and others.

The COVID-19 pandemic had a major influence on healthcare systems across the world, including the markets for ELISpot and FluoroSpot assays. The FluoroSpot assay revealed that COVID-19 patients had the lowest antibody response, whereas three individuals (C4, C5, and C7) had the strongest T-cell responses. ELISpot and FluoroSpot tests are frequently used to evaluate COVID-19 patients' T- and B-cell immunity against SARS-CoV-2. Nonetheless, the industry has recorded a modest fall because COVID-19 instances decreased last year.

Request Sample Pages of Report: https://www.delvens.com/get-free-sample/elispot-and-fluorospot-assay-market-trends-forecast-till-2030

Delvens Industry Expert's Standpoint

The development of new vaccines to combat drug-resistant strains, the rise in the prevalence of chronic diseases worldwide, and technical advancements in ELISpot and FluoroSpot analyzers and assay kits are anticipated to propel market expansion. ELISpot is a vital technique in the creation of vaccines against a number of diseases, such as AIDS, TB, malaria, cancer, and the flu. In clinical investigations to assess vaccinations, the ELISpot test is frequently employed. In comparison to enzyme-linked immunoassays (ELISA) and flow cytometry, the FluoroSpot test based on the ELISpot was found to be more accurate in a June 2021 paper published in the BMC Infectious Diseases Journal (FCM). More than 15 million individuals between the ages of 30 and 69 pass away from NCDs, with low- and middle-income nations accounting for 85% of these early fatalities. As a result, the use of ELISpot and FluroSpot tests for diagnostic purposes is anticipated to expand due to the rising prevalence of chronic illnesses, fueling market expansion.

Key Findings

On the basis of application, The worldwide ELISpot and FluoroSpot test market is divided into diagnostic and research applications based on application. Infectious illnesses, transplants, and other conditions are further divided into sub-segments within the diagnostic applications. The research applications are further divided into the following categories: cancer research, clinical trials, vaccine development, and others. The market for ELISpot and FluoroSpot assays is predicted to be dominated by the diagnostic application sector in 2021 as a result of the rise in chronic infectious illnesses and the usage of point-of-care diagnostics during the pandemic.  

On the basis of end user, The worldwide ELISpot and FluoroSpot assay market is divided into hospitals and clinics, research institutions, pharmaceuticals firms, and other end users based on end user. The ELISpot and FluoroSpot assay market is anticipated to be dominated by hospitals and clinics in 2021 as a result of the availability of improved diagnostic infrastructure and healthcare insurance policies.  

The global ELISpot and FluoroSpot assay market is divided into direct tender and retail sales based on distribution. Due to the availability of a greater number of contacts, increased cost savings, and the assurance of compliance engagements, the direct tender sector is anticipated to dominate the market for ELISpot and FluoroSpot assays in 2021.  

On the basis of product type, The worldwide ELISpot and FluoroSpot test market is divided into three categories based on the kind of product: assay kits, analyzers, and supplemental or ancillary products. The test kit products are further divided into t-cell and cell assays. Due to the increasing demand for cell-based assays in drug discovery and the usage of T-cell assays in cancer research, the assay kits sector is anticipated to dominate the ELISpot and FluoroSpot test market in 2021.  

The global ELISpot and FluoroSpot assay market is divided into the following regions: the United States, Canada and Mexico; Germany, France, the United Kingdom; Italy; Spain; Russia; Belgium; Turkey; Switzerland; the Netherlands; and the rest of Europe; Japan; China; Australia; South Korea; India; Singapore; Thailand; Indonesia; Malaysia; the Philippines; and the rest of Asia-Pacific; Brazil; Argentina; and South Africa; as well as the rest of the Middle East and Africa.

Make an Inquiry Before Buying: https://www.delvens.com/Inquire-before-buying/elispot-and-fluorospot-assay-market-trends-forecast-till-2030

Regional Analysis

North America to Dominate the Market

Due to the widespread availability of ELISpot kits and the usage of the assay kits for vaccine research, North America is predicted to dominate the market.  

Due to the availability of FDA-approved ELISpot and FluoroSpot assay kits, the existence of health reimbursement policies, the growth in chronic infections, and the rise in the older population, the U.S. is leading the worldwide ELISpot and FluoroSpot assay in the North America area.

Competitive Landscape

Oxford immunotec

Cellular Technology Limited

Mabtech

Becton

Abcam plc

Bio-Techne

Mikrogen Diagnostik

Autoimmun Diagnostika

U-CyTech

Medix Biochemica

Merck KGaA

Bio-Sys GmbH

Anogen-Yes Biotech Laboratories

Abnova Corporation

Biorbyt Ltd

Tokyo Chemical Industry

MP BIOMEDICALS

BOC Sciences

ZenBio,Inc

Jackson ImmunoResearch Inc

Krishgen Biosystems

National Analytical Corporation

Stemcell Technologies

Serva Electrophoresis GmbH

Recent Developments

In June 2022, In order to develop a molecular diagnostic test for the Monkeypox virus, an uncommon disease brought on by a virus closely related to the smallpox virus, BD and CerTest Biotec worked together. The partnership seeks to enhance the detection and treatment of infections with monkeypox. The assay will use the BD MAXTM open system reagent suite as part of the cooperation to validate the CerTest VIASURE Monkeypox CE/IVD molecular test on the BD MAXTM System. Users of BD MAXTM will have access to the test, which might increase knowledge of the disease's widespread distribution across the world.  

In April 2022, A service for B-cell ELISpot assays was introduced by ProImmune Ltd. The body's immune defense against viruses, immunological modulators, vaccinations, and therapeutic medications depends heavily on B cells, which are analyzed with the B cell ELISpot test. By counting the amount of B cells that produce a particular antibody in response to a given stimulation, researchers may gauge the effectiveness of vaccinations or the strength of medicinal medications.

Purchase the Report at: https://www.delvens.com/checkout/elispot-and-fluorospot-assay-market-trends-forecast-till-2030

Reasons to Acquire

Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.  

Gain authentic and granular data access for the ELISpot and FluoroSpot Assay Market to understand the trends and the factors involved in changing market situations.  

Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.  

In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope

The ELISpot and FluoroSpot Assay Market is Segmented By Product, Application, End-User and region:

Based on Product Type

Analyzers

Assay kits

Ancillary Products

Based on the End-User

Hospitals & Clinical labs

Biopharmaceutical Company

Research Institutes

Based on the Application

Diagnostic Application

Research Application

Based on Disease

Infectious Disease

Cancer

Autoimmune Disease

Allergy

Other

Based on Source

Human

Mouse

Monkey

Others

Based on region

Asia Pacific  

Japan

China

India

Australia

South Korea

Vietnam

New Zealand

Philippines

Thailand

Malaysia

Hong Kong

Taiwan

Singapore

Indonesia

Sri Lanka

Rest of Asia-Pacific

North America  

U.S.

Canada

Mexico

Europe  

Germany

U.K.

France

Italy

Spain

Sweden

Austria

Finland

Belgium

Turkey

Russia

Poland

Hungary

Czech Republic

Switzerland

Netherlands

Rest of Europe

South America  

Brazil

Argentina

Chile

Colombia

Rest of South America

Middle East & Africa  

South Africa

U.A.E.

Saudi Arabia

Oman

Qatar

Iran

Egypt

Rest of Middle East and Africa

The prominent players in the ELISpot and FluoroSpot Assay market are

Oxford immunotec

Cellular Technology Limited

Mabtech

Becton

Abcam plc

Bio-Techne

Mikrogen Diagnostik

Autoimmun Diagnostika

U-CyTech

Medix Biochemica

Merck KGaA

Bio-Sys GmbH

Anogen-Yes Biotech Laboratories

Abnova Corporation

Biorbyt Ltd

Tokyo Chemical Industry

MP BIOMEDICALS

BOC Sciences

ZenBio,Inc

Jackson ImmunoResearch Inc

Krishgen Biosysystems

National Analytical Corporation

Stemcell Technologies

Serva Electrophoresis GmbH

About Us:

Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally.

Delvens database assists the clients by providing in-depth information in crucial business decisions. Delvens offers significant facts and figures across various industries namely Healthcare, IT & Telecom, Chemicals & Materials, Semiconductor & Electronics, Energy, Pharmaceutical, Consumer Goods & Services, Food & Beverages. Our company provides an exhaustive and comprehensive understanding of the business environment.

Contact Us:

UNIT NO. 2126, TOWER B,

21ST FLOOR ALPHATHUM

SECTOR 90 NOIDA 201305, IN

+44-20-8638-5055

         SALES@DELVENS.COM